2021 Q2 Form 10-Q Financial Statement
#000156459021042217 Filed on August 09, 2021
Income Statement
| Concept | 2021 Q2 | 2020 Q2 |
|---|---|---|
| Revenue | $28.05M | $9.469M |
| YoY Change | 196.22% | -10.03% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $12.55M | $8.640M |
| YoY Change | 45.2% | 7.06% |
| % of Gross Profit | ||
| Research & Development | $25.31M | $17.24M |
| YoY Change | 46.78% | 6.81% |
| % of Gross Profit | ||
| Depreciation & Amortization | $1.121M | $1.060M |
| YoY Change | 5.75% | -10.92% |
| % of Gross Profit | ||
| Operating Expenses | $37.85M | $17.24M |
| YoY Change | 119.53% | -28.78% |
| Operating Profit | -$9.805M | |
| YoY Change | ||
| Interest Expense | $3.653M | $46.29M |
| YoY Change | -92.11% | -42181.82% |
| % of Operating Profit | ||
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | -$6.152M | $29.87M |
| YoY Change | -120.6% | -316.61% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$6.152M | $29.87M |
| YoY Change | -120.59% | -316.57% |
| Net Earnings / Revenue | -21.93% | 315.47% |
| Basic Earnings Per Share | -$0.13 | $1.00 |
| Diluted Earnings Per Share | -$0.13 | $0.94 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 46.12M | 29.90M |
| Diluted Shares Outstanding | 46.12M | 31.78M |
Balance Sheet
| Concept | 2021 Q2 | 2020 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $258.7M | $250.5M |
| YoY Change | 3.28% | 63.51% |
| Cash & Equivalents | $56.39M | $65.35M |
| Short-Term Investments | $202.3M | $185.1M |
| Other Short-Term Assets | $9.751M | $2.900M |
| YoY Change | 236.24% | 11.54% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $9.160M | $5.100M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $277.6M | $258.5M |
| YoY Change | 7.39% | 59.35% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $18.67M | $11.30M |
| YoY Change | 65.21% | 21.86% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $60.01M | $5.600M |
| YoY Change | 971.54% | -62.91% |
| Other Assets | $3.498M | $2.100M |
| YoY Change | 66.57% | -6.21% |
| Total Long-Term Assets | $82.17M | $19.00M |
| YoY Change | 332.49% | -28.54% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $277.6M | $258.5M |
| Total Long-Term Assets | $82.17M | $19.00M |
| Total Assets | $359.8M | $277.5M |
| YoY Change | 29.65% | 46.97% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $7.642M | $4.900M |
| YoY Change | 55.96% | 8.5% |
| Accrued Expenses | $6.510M | $4.500M |
| YoY Change | 44.67% | 26.23% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $3.125M | $0.00 |
| YoY Change | -100.0% | |
| Total Short-Term Liabilities | $26.13M | $35.50M |
| YoY Change | -26.41% | -1.66% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $21.69M | $24.30M |
| YoY Change | -10.72% | 247.14% |
| Other Long-Term Liabilities | $4.469M | $11.00M |
| YoY Change | -59.37% | 8700.0% |
| Total Long-Term Liabilities | $26.16M | $35.30M |
| YoY Change | -25.88% | 395.44% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $26.13M | $35.50M |
| Total Long-Term Liabilities | $26.16M | $35.30M |
| Total Liabilities | $52.29M | $70.80M |
| YoY Change | -26.15% | 2.23% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$264.4M | -$185.5M |
| YoY Change | 42.53% | 10.39% |
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $307.5M | $206.8M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $359.8M | $277.5M |
| YoY Change | 29.65% | 46.97% |
Cashflow Statement
| Concept | 2021 Q2 | 2020 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$6.152M | $29.87M |
| YoY Change | -120.59% | -316.57% |
| Depreciation, Depletion And Amortization | $1.121M | $1.060M |
| YoY Change | 5.75% | -10.92% |
| Cash From Operating Activities | -$5.263M | -$12.50M |
| YoY Change | -57.9% | -19.87% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$5.409M | -$1.770M |
| YoY Change | 205.59% | 261.22% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $11.28M | -$55.37M |
| YoY Change | -120.38% | -672.0% |
| Cash From Investing Activities | $5.876M | -$57.14M |
| YoY Change | -110.28% | -721.76% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -43.00K | 91.42M |
| YoY Change | -100.05% | -11248.78% |
| NET CHANGE | ||
| Cash From Operating Activities | -5.263M | -12.50M |
| Cash From Investing Activities | 5.876M | -57.14M |
| Cash From Financing Activities | -43.00K | 91.42M |
| Net Change In Cash | 570.0K | 21.78M |
| YoY Change | -97.38% | -401.24% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$5.263M | -$12.50M |
| Capital Expenditures | -$5.409M | -$1.770M |
| Free Cash Flow | $146.0K | -$10.73M |
| YoY Change | -101.36% | -28.99% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| us-gaap |
Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
|
false | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.846 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.732 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.849 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.840 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.006 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.002 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.011 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.016 | ||
| CY2021Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
0 | ||
| CY2020Q2 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
0 | |
| us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
2813000 | ||
| CY2020Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
29900913 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
46007892 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
26510873 | ||
| CY2020Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
31777960 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
46007892 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28538279 | ||
| CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
29872000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-36511000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
10277000 | ||
| CY2020Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
370000 | |
| us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-174000 | ||
| us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
233000 | ||
| CY2020Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
30242000 | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-36685000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
10510000 | ||
| CY2021Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2021Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2021Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2021Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2021Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
| CY2021Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
46141454 | |
| CY2021Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
46141454 | |
| CY2021Q2 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
0 | |
| CY2021Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
28049000 | |
| CY2021Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
12545000 | |
| CY2021Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
37854000 | |
| CY2021Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
46116175 | |
| CY2021Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
46116175 | |
| CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6152000 | |
| CY2021Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-45000 | |
| CY2021Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-6197000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
332048000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1360000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
873000 | |
| CY2021Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
407000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3952000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
307338000 | |
| CY2021Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
452000 | |
| CY2020Q1 | stro |
Warrants Issued During Period Value In Connection With Debt Refinancing
WarrantsIssuedDuringPeriodValueInConnectionWithDebtRefinancing
|
619000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
8000 | |
| CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5907000 | |
| CY2021Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-45000 | |
| CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6152000 | |
| CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
307500000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
56000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
646000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2707000 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3011000 | |
| CY2020Q2 | stro |
Common Stock Issuance Costs
CommonStockIssuanceCosts
|
6626000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
91411000 | |
| CY2020Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
370000 | |
| CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
29872000 | |
| CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
206757000 | |
| us-gaap |
Profit Loss
ProfitLoss
|
10277000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9859000 | ||
| us-gaap |
Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
|
-6364000 | ||
| us-gaap |
Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
|
48860000 | ||
| stro |
Remeasurement Of Liability Awards
RemeasurementOfLiabilityAwards
|
-25000 | ||
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-258000 | ||
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-322000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
3601000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-1196000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
5265000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1475000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1742000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1969000 | ||
| us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-2313000 | ||
| us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-1497000 | ||
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
434000 | ||
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-413000 | ||
| us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
-2092000 | ||
| us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
79000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-12382000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-1595000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-35693000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-31234000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
202315000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
91270000 | ||
| stro |
Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
|
85250000 | ||
| stro |
Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
|
63800000 | ||
| stro |
Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
|
9000000 | ||
| stro |
Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
|
14500000 | ||
| stro |
Payments To Acquire Equipment And Leasehold Improvements
PaymentsToAcquireEquipmentAndLeaseholdImprovements
|
7789000 | ||
| stro |
Payments To Acquire Equipment And Leasehold Improvements
PaymentsToAcquireEquipmentAndLeaseholdImprovements
|
2529000 | ||
| us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
98038000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
491000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
6627000 | ||
| us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
25000000 | ||
| us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
10000000 | ||
| CY2021Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
72000 | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1812000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
64000 | ||
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
646000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1787000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
107121000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-149760000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
60388000 | ||
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
207024000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
4975000 | |
| CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
57264000 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
65363000 | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
1020000 | ||
| us-gaap |
Interest Paid Net
InterestPaidNet
|
649000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
1376000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
1286000 | ||
| stro |
Embedded Interest Associated With Program Fees
EmbeddedInterestAssociatedWithProgramFees
|
412000 | ||
| stro |
Embedded Interest Associated With Program Fees
EmbeddedInterestAssociatedWithProgramFees
|
1128000 | ||
| stro |
Warrants Issued To Lenders
WarrantsIssuedToLenders
|
619000 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and Principal Activities</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sutro Biopharma, Inc. (the “Company”), is a clinical stage drug discovery, development and manufacturing company focused on leveraging its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup>, to create a broad variety of optimally designed, next-generation protein therapeutics, initially for cancer and autoimmune disorders. The Company was incorporated on April 21, 2003 and is headquartered in South San Francisco, California. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one business segment, the development of biopharmaceutical products. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred significant losses and has negative cash flows from operations. As of June 30, 2021, the Company had an accumulated deficit of $264.4 million. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development and other operational activities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2021, the Company had unrestricted cash, cash equivalents and marketable securities of $283.4 million, which is available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and to support its operations.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its unrestricted cash, cash equivalents and marketable securities as of June 30, 2021 will enable the Company to maintain its operations for a period of at least 12 months following the filing date of its financial statements. </p> | ||
| dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2003-04-21 | ||
| dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
South San Francisco | ||
| dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | ||
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
| CY2021Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-264400000 | |
| CY2021Q2 | stro |
Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value
UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue
|
283400000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
324845000 | |
| CY2021Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
56392000 | |
| CY2020Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
65348000 | |
| CY2021Q2 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
872000 | |
| CY2020Q2 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
15000 | |
| CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
57264000 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
65363000 | |
| CY2021Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
285047000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
131000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
324973000 | |
| CY2021Q2 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
60000000.0 | |
| CY2020Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
0 | |
| CY2021Q2 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
|
93800000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
|
14700000 | |
| CY2021Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
72000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000 | |
| us-gaap |
Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
|
0 | ||
| us-gaap |
Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
|
0 | ||
| CY2021Q2 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
8100000 | |
| CY2021Q2 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P12M | |
| CY2020Q4 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
200000 | |
| CY2021Q2 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
200000 | |
| CY2021Q2 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
600000 | |
| us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
1300000 | ||
| CY2021Q2 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.0807 | |
| CY2021Q2 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
100000 | |
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
300000 | ||
| CY2020Q2 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
600000 | |
| us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
1000000.0 | ||
| CY2020Q2 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.0807 | |
| us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.0807 | ||
| us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.0808 | ||
| CY2020Q2 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
100000 | |
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
200000 | ||
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
300000 | |
| CY2021Q2 | stro |
Lessee Operating Sublease Liability Payments Due After Year Four
LesseeOperatingSubleaseLiabilityPaymentsDueAfterYearFour
|
17265000 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
2200000 | ||
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
5000 | |
| CY2021Q2 | stro |
Lessee Operating Sublease Liability Payments Remainder Of Fiscal Year
LesseeOperatingSubleaseLiabilityPaymentsRemainderOfFiscalYear
|
4538000 | |
| CY2021Q2 | stro |
Lessee Operating Sublease Liability Payments Due Next Twelve Months
LesseeOperatingSubleaseLiabilityPaymentsDueNextTwelveMonths
|
6793000 | |
| CY2021Q2 | stro |
Lessee Operating Sublease Liability Payments Due Year Two
LesseeOperatingSubleaseLiabilityPaymentsDueYearTwo
|
7969000 | |
| CY2021Q2 | stro |
Lessee Operating Sublease Liability Payments Due Year Three
LesseeOperatingSubleaseLiabilityPaymentsDueYearThree
|
9184000 | |
| CY2021Q2 | stro |
Lessee Operating Sublease Liability Payments Due Year Four
LesseeOperatingSubleaseLiabilityPaymentsDueYearFour
|
9497000 | |
| CY2021Q2 | stro |
Lessee Operating Sublease Liability Payments Due
LesseeOperatingSubleaseLiabilityPaymentsDue
|
55246000 | |
| stro |
Potential Financial Benefit Base Rent Abatement
PotentialFinancialBenefitBaseRentAbatement
|
5200000 | ||
| us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
one vote per share | ||
| CY2021Q2 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
10674126 | |
| CY2020Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
8331103 | |
| CY2021Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2021Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
81000 | ||
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
12.84 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
14.71 | ||
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.60 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.03 | ||
| CY2021Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5907000 | |
| CY2020Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3011000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9859000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5718000 | ||
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
266724 | |
| CY2021Q2 | stro |
Liability Attributable To Call Option Plan
LiabilityAttributableToCallOptionPlan
|
137000 | |
| CY2020Q4 | stro |
Liability Attributable To Call Option Plan
LiabilityAttributableToCallOptionPlan
|
109000 | |
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
257834 | ||
| CY2020 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
257834 | |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4445 | |
| CY2021Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
4445 | |
| CY2020Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
8890 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
266724 | ||
| CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6152000 | |
| CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
29872000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-36511000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
10277000 | ||
| CY2021Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
46116175 | |
| CY2020Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
29900913 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
46007892 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
26510873 | ||
| CY2021Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
46116175 | |
| CY2020Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
31777960 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
46007892 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28538279 | ||
| CY2021Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.13 | |
| CY2020Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
1.00 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.79 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.39 | ||
| CY2021Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.13 | |
| CY2020Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.94 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.79 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.36 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8429329 |
